Pharma and Biotech Daily: Roche's Breast Cancer Drug Approval, Teva's Settlement, and Biotech Industry Updates

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has received regulatory approval for its breast cancer drug, inavolisib, for advanced breast cancer, projecting $2.3 billion in peak sales. This drug is seen as a potential competitor to Novartis' pi3k inhibitor piqray.Teva has agreed to pay $450 million in a settlement with the Department of Justice over kickback and price-fixing allegations. Upstream Bio raised $255 million in an IPO for inflammatory disease work, while Camp4 Therapeutics received $75 million for RNA-targeting drug development.Senator Elizabeth Warren has expressed concerns about Novo Nordisk's $16.5 billion acquisition of Catalent, warning that it could reduce competition in the market. Genscript is hosting the Biotech Global Forum 2025 on January 15, 2025, focusing on gene and cell therapy innovations.Stealth received support for ultra-rare disease drugs, Sanofi and Denali abandoned a multiple sclerosis study, and Lilly is facing challenges in its obesity clinical program. Layoffs have been announced at Medtronic, CareFusion, and Turnstone Biologics. For job opportunities in the biotech industry, Recursion, NKarta Inc., Foresight Diagnostics, and Insmed Incorporated are hiring for various positions.